- Conditions
- Patients
- Interventions
- Empagliflozin, Dorzagliatin
- Drug
- Lead sponsor
- Hua Medicine Limited
- Industry
- Eligibility
- 30 Years to 65 Years
- Enrollment
- 16 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2020
- U.S. locations
- 1
- States / cities
- Hackensack, New Jersey
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 1–12
of 12
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Diabetes Mellitus, Type 2, Hypertension
- Interventions
- Placebo, BI 10773
- Drug
- Lead sponsor
- Boehringer Ingelheim
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 825 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2012
- U.S. locations
- 35
- States / cities
- Huntsville, Alabama • Phoenix, Arizona • Lincoln, California + 29 more
- Conditions
- Partial Islet Function, TPIAT, Diabetes
- Interventions
- Empagliflozin 25 MG Oral Tablet, Empagliflozin 10 MG Oral Tablet [Jardiance]
- Drug
- Lead sponsor
- University of Minnesota
- Other
- Eligibility
- 18 Years to 70 Years
- Enrollment
- 40 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2028
- U.S. locations
- 1
- States / cities
- Minneapolis, Minnesota
- Conditions
- Diabetes Mellitus, Type 2
- Interventions
- Semaglutide, Empagliflozin, Metformin
- Drug
- Lead sponsor
- Novo Nordisk A/S
- Industry
- Eligibility
- 18 Years to 60 Years
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2027
- U.S. locations
- 1
- States / cities
- Waco, Texas
- Conditions
- Pre-Diabetes, Weight, Body, Cardiovascular Diseases
- Interventions
- Placebo, Rybelsus Tablet, Jardiance 25Mg Tablet, Metformin, Actos
- Drug
- Lead sponsor
- The University of Texas Health Science Center at San Antonio
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 64 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2027
- U.S. locations
- 1
- States / cities
- San Antonio, Texas
- Conditions
- Type2diabetes, Heart Failure With Reduced Ejection Fraction
- Interventions
- Empagliflozin 25 MG Oral Tablet, Placebo, Acipimox 250 Mg Oral Capsule
- Drug
- Lead sponsor
- The University of Texas Health Science Center at San Antonio
- Other
- Eligibility
- 18 Years to 70 Years
- Enrollment
- 71 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2027
- U.S. locations
- 1
- States / cities
- San Antonio, Texas
- Conditions
- Diabetes Mellitus, Type 2
- Interventions
- BI 10773 low dose, Placebo BI 10773 high dose, BI 10773 high dose, Placebo BI 10773 low dose
- Drug
- Lead sponsor
- Boehringer Ingelheim
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 7,064 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2015
- U.S. locations
- 170
- States / cities
- Birmingham, Alabama • Huntsville, Alabama • Mobile, Alabama + 140 more
- Conditions
- Diabetes Mellitus, Type 2
- Interventions
- Placebo identical to BI 10773 high dose, Placebo identical to BI 10773 low dose, BI 10773
- Drug
- Lead sponsor
- Boehringer Ingelheim
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 1,504 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Started 2010
- U.S. locations
- 25
- States / cities
- Birmingham, Alabama • Tempe, Arizona • Huntington Park, California + 21 more
- Conditions
- Diabetes Mellitus, Type 2
- Interventions
- Linagliptin, Empagliflozin + Linagliptin, Empagliflozin placebo + Linagliptin placebo
- Drug
- Lead sponsor
- Boehringer Ingelheim
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 607 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2015
- U.S. locations
- 28
- States / cities
- Gulf Shores, Alabama • Norwalk, California • San Diego, California + 24 more
- Conditions
- Diabetes Mellitus, Type 2
- Interventions
- high dose FDC, BI 10773 high dose, high dose FDC placebo, low dose FDC placebo, high dose BI 10773 placebo, low dose FDC, BI 10773 low dose, linagliptin, linagliptin placebo, BI 10773 low dose placebo, low dose BI 10773 placebo
- Drug
- Lead sponsor
- Boehringer Ingelheim
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 1,405 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2013
- U.S. locations
- 112
- States / cities
- Birmingham, Alabama • Foley, Alabama • Mobile, Alabama + 90 more
- Conditions
- Diabetes Mellitus, Type 2
- Interventions
- Placebo, BI 10773
- Drug
- Lead sponsor
- Boehringer Ingelheim
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 499 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Started 2010
- U.S. locations
- 24
- States / cities
- Muscle Shoals, Alabama • Glendale, Arizona • Phoenix, Arizona + 21 more
- Conditions
- Diabetes Mellitus, Type 2, Obesity
- Interventions
- Placebo, BI 10773
- Drug
- Lead sponsor
- Boehringer Ingelheim
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 566 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2013
- U.S. locations
- 26
- States / cities
- Birmingham, Alabama • Chandler, Arizona • Tucson, Arizona + 23 more